PreveCeutical's Subsidary, Biogene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced two key appointments at its subsidiary BioGene Therapeutics Inc. Dr. Linnea Olofsson joins as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer, effective November 16, 2024. Dr. Parekh brings over two decades of experience in pharmaceutical chemistry and drug/gene delivery systems from The University of Queensland's School of Pharmacy. Dr. Olofsson contributes expertise in biophysics, oncology, molecular biology, and CRISPR/Cas9 gene editing. These appointments aim to advance BioGene's scientific initiatives and therapeutic applications development.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) ha annunciato due nomine importanti presso la sua filiale BioGene Therapeutics Inc. Dr. Linnea Olofsson si unisce come Chief Scientific Officer e Dr. Harry Parekh come Chief Research Officer, a partire dal 16 novembre 2024. Il Dr. Parekh porta oltre vent'anni di esperienza in chimica farmaceutica e sistemi di somministrazione di farmaci/geni dalla Scuola di Farmacia dell'Università del Queensland. La Dr.ssa Olofsson contribuisce con la sua esperienza in biofisica, oncologia, biologia molecolare e editing genetico CRISPR/Cas9. Queste nomine mirano ad avanzare le iniziative scientifiche di BioGene e lo sviluppo delle applicazioni terapeutiche.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) ha anunciado dos nombramientos clave en su filial BioGene Therapeutics Inc. Dr. Linnea Olofsson se une como Directora Científica y Dr. Harry Parekh como Director de Investigación, con efecto a partir del 16 de noviembre de 2024. El Dr. Parekh aporta más de dos décadas de experiencia en química farmacéutica y sistemas de entrega de fármacos/genéticos de la Facultad de Farmacia de la Universidad de Queensland. La Dra. Olofsson aporta experiencia en biofísica, oncología, biología molecular y edición genética CRISPR/Cas9. Estos nombramientos tienen como objetivo avanzar en las iniciativas científicas de BioGene y en el desarrollo de aplicaciones terapéuticas.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)는 자회사인 BioGene Therapeutics Inc.에서 두 가지 주요 임명을 발표했습니다. Dr. Linnea Olofsson가 최고 과학 책임자로 합류하고, Dr. Harry Parekh가 최고 연구 책임자로 2024년 11월 16일부터 임명됩니다. Parekh 박사는 퀸즐랜드 대학교 약학대학에서 의약 화학 및 약물/유전자 전달 시스템에서 20년 이상의 경험을 가지고 있습니다. Olofsson 박사는 생물물리학, 종양학, 분자 생물학 및 CRISPR/Cas9 유전자 편집에 대한 전문 지식을 기여합니다. 이러한 임명은 BioGene의 과학적 이니셔티브와 치료 응용 프로그램 개발을 진전시키기 위한 것입니다.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) a annoncé deux nominations clés au sein de sa filiale BioGene Therapeutics Inc. Dr. Linnea Olofsson rejoint l'entreprise en tant que Directrice Scientifique et Dr. Harry Parekh en tant que Directeur de la Recherche, à compter du 16 novembre 2024. Le Dr. Parekh apporte plus de vingt ans d'expérience en chimie pharmaceutique et systèmes de délivrance de médicaments/gènes de l'École de Pharmacie de l'Université du Queensland. La Dr. Olofsson apporte son expertise en biophysique, oncologie, biologie moléculaire et édition génétique CRISPR/Cas9. Ces nominations visent à faire avancer les initiatives scientifiques de BioGene et le développement d'applications thérapeutiques.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) hat zwei wichtige Ernennungen bei seiner Tochtergesellschaft BioGene Therapeutics Inc. bekannt gegeben. Dr. Linnea Olofsson tritt als Chief Scientific Officer und Dr. Harry Parekh als Chief Research Officer, ab dem 16. November 2024, bei. Dr. Parekh bringt über zwei Jahrzehnte Erfahrung in pharmazeutischer Chemie und Wirkstoff-/Genabgabesystemen von der School of Pharmacy der University of Queensland mit. Dr. Olofsson leistet einen Beitrag mit ihrer Expertise in Biophysik, Onkologie, Molekularbiologie und CRISPR/Cas9-Genbearbeitung. Diese Ernennungen zielen darauf ab, die wissenschaftlichen Initiativen von BioGene und die Entwicklung therapeutischer Anwendungen voranzutreiben.
- Strategic appointment of two experienced scientific leaders strengthening the research and development team
- Dr. Parekh brings over 20 years of expertise in pharmaceutical chemistry and drug delivery systems
- Dr. Olofsson adds valuable expertise in advanced biotechnology including CRISPR/Cas9 gene editing
- None.
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. announce the appointments of Dr. Linnea Olofsson as Chief Scientific Officer (CSO) and Dr. Harry Parekh as Chief Research Officer (CRO), effective 16 November, 2024.
Stephen Van Deventer, CEO of BioGene, commented:
"The appointments of Dr. Olofsson and Dr. Parekh are pivotal milestones for BioGene as we position ourselves at the forefront of scientific innovation and leadership in the life sciences sector. Harry's visionary contributions to drug and gene delivery technologies, coupled with Linnea's profound expertise and interdisciplinary approach, will undoubtedly propel our company into its next phase of growth and success."
Dr. Harry Parekh: Driving Innovation in Drug and Gene Delivery Systems
Dr. Parekh, is a recognized leader in pharmaceutical chemistry, and its application in the formulation of advanced drug/gene delivery platform systems. His groundbreaking work at The University of Queensland's School of Pharmacy leverages over two decades of experience; this spans the design, development and validation of innovative chemistries/formulations for tissue-targeted, controlled and sustained therapeutic delivery. His pursuits have focused on addressing critical challenges and bottlenecks impeding the translation of precision medicine for both rare and mainstream disease. As CRO, Dr. Parekh will oversee the validation and translation of BioGene's innovative research platforms into real-world therapeutic applications, assuring the company's technologies achieve maximum impact, benefit and reach for patients, globally.
Dr. Linnea Olofsson: Bridging Science and Strategy
Dr. Olofsson brings a wealth of experience as an accomplished biophysicist with expertise spanning oncology, molecular biology, CRISPR/Cas9 gene editing, and advanced microscopy techniques. Her extensive knowledge of time-resolved microscopy and spectroscopy, single-molecule detection, and fluorescence super-resolution microscopy, structure-based drug design and dynamics, pharmacology and cell biology underpins her scientific acumen. Linnea's interdisciplinary approach and collaborative work with Dr. Parekh have provided her with a comprehensive understanding of BioGene's scientific priorities and opportunities for innovation.
Dr. Olofsson has demonstrated a remarkable ability to align complex scientific research with strategic objectives, facilitating the advancement of cutting-edge therapies. Her focus as CSO will be on steering BioGene's scientific initiatives to align with its mission to deliver transformative treatments, ensuring robust scientific integrity and excellence.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the advancement of our siRNA therapy; and PreveCeutical's aim to be a leader in preventive health sciences. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company, including regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230351
FAQ
When did PreveCeutical Medical (PRVCF) appoint its new CSO and CRO at BioGene Therapeutics?
What is Dr. Harry Parekh's background at PreveCeutical Medical (PRVCF)?
What is Dr. Linnea Olofsson's expertise as the new CSO of PreveCeutical's (PRVCF) BioGene Therapeutics?
